Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
暂无分享,去创建一个
[1] M. Ghielmini,et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. , 2010, Journal of the National Cancer Institute.
[2] M. Ghielmini,et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Salles,et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. , 2010 .
[4] Giovanni Martinelli,et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Rossi,et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.
[6] R. Marcus,et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] B. Coiffier,et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Mclaughlin,et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. , 2008, Blood.
[9] A. Levis,et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. , 2008, Blood.
[10] G. Schwarzer,et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.
[11] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Trümper,et al. Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma—role of radioimmunotherapy , 2007, Annals of Hematology.
[13] G. Salles,et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 2006, Blood.
[14] E. Hoster,et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect , 2006, Blood.
[15] P. Solal-Céligny,et al. Follicular lymphoma international prognostic index , 2006, Blood.
[16] A. Hagenbeek,et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Richard L Wahl,et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. , 2005, The New England journal of medicine.
[18] L. Staudt,et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.
[19] V. Diehl,et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. , 2004, Blood.
[20] Ruta Bajorunaite,et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. , 2003, Blood.
[21] M. Sydes,et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] K. Maclennan,et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.
[23] A. Rosenwald,et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. , 2002, Blood.
[24] M. M. Mac Manus,et al. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Gordon,et al. Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma , 2009 .